Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers ; volume:21 ; number:1 ; day:24 ; month:2 ; year:2022 ; pages:1-22 ; date:12.2022
Molecular cancer ; 21, Heft 1 (24.2.2022), 1-22, 12.2022
- Creator
-
Kolesar, Jill
Peh, Spencer
Thomas, Levin
Baburaj, Gayathri
Mukherjee, Nayonika
Kantamneni, Raveena
Lewis, Shirley
Pai, Ananth
Udupa, Karthik S.
Kumar AN, Naveena
Rangnekar, Vivek M.
Rao, Mahadev
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12943-022-01534-8
- URN
-
urn:nbn:de:101:1-2022052619113932966412
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kolesar, Jill
- Peh, Spencer
- Thomas, Levin
- Baburaj, Gayathri
- Mukherjee, Nayonika
- Kantamneni, Raveena
- Lewis, Shirley
- Pai, Ananth
- Udupa, Karthik S.
- Kumar AN, Naveena
- Rangnekar, Vivek M.
- Rao, Mahadev
- SpringerLink (Online service)
Other Objects (12)
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Pharmacogenomics
NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers
6th Golden Helix Pharmacogenomics Day: pharmacogenomics and individualized therapy
The pharmacogenomics journal
Pharmacogenomics and toxicogenomics
Pharmacogenomics and toxicogenomics
Clinical use of pharmacogenomics
Pharmacogenomics of neuropathic pain
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Status of Sentinel Lymph Node Biopsy in Gynecological Cancers
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Pharmacogenomics
NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers
6th Golden Helix Pharmacogenomics Day: pharmacogenomics and individualized therapy
The pharmacogenomics journal
Pharmacogenomics and toxicogenomics
Pharmacogenomics and toxicogenomics
Clinical use of pharmacogenomics
Pharmacogenomics of neuropathic pain
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
Status of Sentinel Lymph Node Biopsy in Gynecological Cancers
Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
Pharmacogenomics
NF-κB-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers
6th Golden Helix Pharmacogenomics Day: pharmacogenomics and individualized therapy
The pharmacogenomics journal
Pharmacogenomics and toxicogenomics
Pharmacogenomics and toxicogenomics
Clinical use of pharmacogenomics
Pharmacogenomics of neuropathic pain
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI
Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC